glp-1 drugs long term effects of glp 1 Part 2 of a 3-Part Series; GLP-1 drugs calm inflammation beyond

High-throughput virtual screening of proteins using GRID molecular interaction fields

The long-acting GLP-1 receptor agonists segment dominated the market with the largest revenue share of 55.5% in 2024, driven by their superior efficacy in sustained weight loss, cardiovascular benefits, and the convenience of once-weekly dosing

These findings are important as they may broaden the indications for these medications and benefit a larger patient population, added Mir Ali, MD, a general surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA

In conclusion, our study conducted within real-world clinical settings revealed a noteworthy association between the use of GLP-1 RAs, including Liraglutide and Semaglutide, and a heightened risk of psychiatric outcomes, encompassing depression, anxiety, and suicidal behaviour

The addition of an SGLT-2 inhibitor to existing GLP-1 receptor agonist use was also associated with a reduced risk of cardiovascular mortality and heart failure compared with GLP-1 receptor agonists alone

Here, Teladoc UK's David Griffiths discusses what this means and how they work: To view or add a comment, sign in The clinical trials for semaglutide used the base form of the moleculenot the sodium or acetate salt variants showing up in much of the compounded injectable market, and independent testing suggests the quality gap is larger than most prescribers realize